Clopidogrel hypersensitivity, which affects 6% of patients, can be successfully treated using short-course corticosteroids and antihistamines without interrupting drug therapy, reported researchers at Jefferson Medical College in Philadelphia.
Clopidogrel hypersensitivity, which affects 6% of patients, can be successfully treated using short-course corticosteroids and antihistamines without interrupting drug therapy, reported researchers at Jefferson Medical College in Philadelphia.
The study population consisted of 25 consecutive patients showing clopidogrel hypersensitivity after percutaneous coronary intervention. They had developed clopidogrel hypersensitivity 6 ± 2 days after drug initiation. The patients were treated with corticosteroids (5 patients), antihistamines (5 patients), or corticosteroids and antihistamines (15 patients). Patients treated with corticosteroids received a tapering course for a mean of 10 ± 8 days.
Suppressive therapy resulted in sustained symptom resolution in 22 of 25 patients (88%). Patients who were successfully desensitized continued clopidogrel therapy for 417 ± 369 days; 16 patients with drug-eluting stents continued for 529 ± 376 days. No deaths, myocardial infarctions, or stent thrombosis occurred during the extended follow-up period.
"Clopidogrel hypersensitivity can be successfully treated using short-course corticosteroids and antihistamines without interrupting therapy," the authors concluded. "This technique enables long-term continuation of clopidogrel and confers a low risk of adverse cardiac events.”
The report was published in the March 15th edition of the American Journal of Cardiology.
FDA Approves Combination Therapy for Pulmonary Arterial Hypertension
March 25th 2024J&J’s Opsynvi is single-tablet combination of macitentan, an endothelin receptor antagonist, and tadalafil, a PDE5 inhibitor. It will be priced on parity with Opsumit, which is also a J&J product to treat patients with PAH.
FDA Issues Complete Response Letter for Onpattro in Heart Failure Indication
October 9th 2023Alnylam Pharmaceuticals will no longer pursue this indication of Onpattro and will instead on focus on a label expansion for Amvuttra, which is in phase 3 development to treat patients with cardiomyopathy of ATTR amyloidosis.